Insider Buying: Rein Therapeutics (NASDAQ:RNTX) Insider Purchases $25,000.00 in Stock

Rein Therapeutics Inc. (NASDAQ:RNTX) insider James Brian Windsor acquired 25,000 shares of the firm’s stock in a transaction dated Thursday, April 30th. The shares were purchased at an average price of $1.00 per share, with a total value of $25,000.00. Following the acquisition, the insider owned 27,046 shares of the company’s stock, valued at approximately $27,046. This represents a 1,221.90% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Rein Therapeutics Stock Down 7.1%

NASDAQ RNTX opened at $1.05 on Friday. The company has a market cap of $29.44 million, a price-to-earnings ratio of -0.54 and a beta of 1.42. Rein Therapeutics Inc. has a 52 week low of $1.00 and a 52 week high of $2.36. The business has a 50 day moving average price of $1.37 and a 200-day moving average price of $1.34.

Rein Therapeutics (NASDAQ:RNTX) last announced its earnings results on Friday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.30. On average, equities research analysts anticipate that Rein Therapeutics Inc. will post -1.63 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on RNTX shares. Wall Street Zen raised Rein Therapeutics to a “sell” rating in a research report on Saturday. cut Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Thursday, January 22nd. Finally, Citigroup cut Rein Therapeutics to a “hold” rating in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Susquehanna International Group LLP bought a new position in Rein Therapeutics in the 3rd quarter valued at $35,000. HRT Financial LP bought a new position in Rein Therapeutics in the 4th quarter valued at $38,000. Chicago Partners Investment Group LLC grew its stake in Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after purchasing an additional 10,000 shares during the period. Northwestern Mutual Wealth Management Co. bought a new position in Rein Therapeutics in the 2nd quarter valued at $68,000. Finally, Jane Street Group LLC bought a new position in Rein Therapeutics in the 4th quarter valued at $72,000. Institutional investors own 90.89% of the company’s stock.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.